| 000 | 01695 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518093332.0 | ||
| 264 | 0 | _c20201214 | |
| 008 | 202012s 0 0 eng d | ||
| 022 | _a1873-2968 | ||
| 024 | 7 |
_a10.1016/j.bcp.2020.113938 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOrtega Ugalde, Sandra | |
| 245 | 0 | 0 |
_aAcetylene containing cyclo(L-Tyr-L-Tyr)-analogs as mechanism-based inhibitors of CYP121A1 from Mycobacterium tuberculosis. _h[electronic resource] |
| 260 |
_bBiochemical pharmacology _c07 2020 |
||
| 300 |
_a113938 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcetylene _xchemistry |
| 650 | 0 | 4 |
_aAntitubercular Agents _xchemistry |
| 650 | 0 | 4 | _aCatalytic Domain |
| 650 | 0 | 4 | _aCyclization |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme Inhibitors _xchemistry |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xchemistry |
| 650 | 0 | 4 |
_aDiketopiperazines _xmetabolism |
| 650 | 0 | 4 |
_aDipeptides _xchemistry |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aEscherichia coli _xgenetics |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 |
_aPeptides, Cyclic _xchemistry |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 |
_aTuberculosis _xmetabolism |
| 650 | 0 | 4 |
_aTyrosine _xanalogs & derivatives |
| 700 | 1 | _aWallraven, Kerstin | |
| 700 | 1 | _aSpeer, Alexander | |
| 700 | 1 | _aBitter, Wilbert | |
| 700 | 1 | _aGrossmann, Tom N | |
| 700 | 1 | _aCommandeur, Jan N M | |
| 773 | 0 |
_tBiochemical pharmacology _gvol. 177 _gp. 113938 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bcp.2020.113938 _zAvailable from publisher's website |
| 999 |
_c30792012 _d30792012 |
||